DrugPatentWatch Database Preview
INGREZZA Drug Profile
Which patents cover Ingrezza, and when can generic versions of Ingrezza launch?
Ingrezza is a drug marketed by Neurocrine and is included in one NDA. There are three patents protecting this drug.
This drug has twenty-six patent family members in sixteen countries.
The generic ingredient in INGREZZA is valbenazine tosylate. One supplier is listed for this compound. Additional details are available on the valbenazine tosylate profile page.
Summary for INGREZZA
| International Patents: | 26 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 17 |
| Patent Applications: | 11 |
| Drug Prices: | Drug price information for INGREZZA |
| DailyMed Link: | INGREZZA at DailyMed |
Generic Entry Opportunity Date for INGREZZA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for INGREZZA
| Drug Class | Vesicular Monoamine Transporter 2 Inhibitor |
| Mechanism of Action | Vesicular Monoamine Transporter 2 Inhibitors |
Synonyms for INGREZZA
| (2R,3R,11bR)-9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl L-valinate |
| (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester |
| [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl] (2S)-2-amino-3-methylbutanoate |
| 1025504-45-3 |
| 54K37P50KH |
| AKOS027321089 |
| CHEMBL2364639 |
| CS-5908 |
| D0IX1I |
| D10675 |
| DB11915 |
| GEJDGVNQKABXKG-CFKGEZKQSA-N |
| GTPL8694 |
| HY-16771 |
| L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester |
| L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester;L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl est |
| MFCD28963976 |
| MolPort-044-723-889 |
| NBI 98854 |
| NBI-98854;NBI98854;NBI 98854 |
| SCHEMBL15932979 |
| UNII-54K37P50KH |
| Valbenazine |
| Valbenazine (USAN/INN) |
| Valbenazine [USAN:INN] |
| Valbenazine pound NBI-98854 pound(c) |
| Vesicular monoamine transporter 2 inhibitor (CNS indications), Neurocrine |
| VMAT-2 inhibitor (CNS disease), Neurocrine |
| ZINC43195697 |
US Patents and Regulatory Information for INGREZZA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for INGREZZA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| China | 101553487 | ➤ Sign Up |
| Singapore | 11201803408P | ➤ Sign Up |
| Mexico | 2018005136 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
